MedTrace Logo

Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy

NCT00801177 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-10-13

No results posted yet for this study

Summary

The purpose of this study is to determine if IMC-11F8 is safe for patients, and also to determine the best dose of IMC-11F8 to give to patients.

Conditions

Interventions

BIOLOGICAL

IMC-11F8

Cohort 1 100 mg I.V.

BIOLOGICAL

IMC-11F8

Cohort 2 200 mg I.V.

BIOLOGICAL

IMC-11F8

Cohort 3 400 mg I.V.

BIOLOGICAL

IMC-11F8 I.V.

Cohort 4 600 mg I.V.

BIOLOGICAL

IMC-11F8

Cohort 5 800 mg I.V.

BIOLOGICAL

IMC-11F8

Cohort 6 1000 mg I.V.

BIOLOGICAL

IMC-11F8

Cohort 1 100 mg I.V.

BIOLOGICAL

IMC-11F8

Cohort 2 200 mg I.V.

BIOLOGICAL

IMC-11F8

Cohort 3 400 mg I.V.

BIOLOGICAL

IMC-11F8

Cohort 4 600 mg I.V.

BIOLOGICAL

IMC-11F8

Cohort 5 800 mg I.V.

BIOLOGICAL

IMC-11F8

Cohort 6 1000 mg I.V.

Sponsors & Collaborators

Principal Investigators

  • E-mail: ClinicalTrials@ ImClone.com · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2007-02-28
Completion
2007-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00801177 on ClinicalTrials.gov